Företrädesemissionen i GPX Medical AB (publ) (“GPX Medical” eller “Bolaget”) om cirka 27,4 miljoner SEK före emissionskostnader har idag registrerats hos Bolagsverket och betald tecknad aktie (BTA) kommer därmed att ersättas av stamaktier. Sista dag för handel med BTA är den 28 oktober 2021 och nya aktier beräknas att bokas in på respektive depå/VP-konto den 3 november 2021.

Läs pressmeddelandet i sin helhet här: Pressmeddelande

About GPX Medical

GPX Medical AB (publ) is revolutionizing neonatal intensive care with NEOLA®, a medical device that can offer continuous lung monitoring and real-time alerts of life-threatening complications using a cutting-edge technology that measures lung volume changes and oxygen gas concentration. NEOLA® has the potential to provide better care, fewer days in intensive care and healthier lives for preterm born infants. Founded in 2016 and headquartered in Lund, Sweden, GPX Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care.

For investors

Please contact CEO Hanna Sjöström for investment opportunities:
hanna.sjostrom@gpxmedical.se

Contact

GPX Medical AB (publ)
Ideon Science Park
Scheelevägen 27
223 63 Lund
info@gpxmedical.se

Organization number: 559069-9012